Disc Medicine, Inc. $IRON Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. lifted its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 3.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,448,059 shares of the company’s stock after purchasing an additional 51,323 shares during the period. Vanguard Group Inc. owned approximately 4.16% of Disc Medicine worth $95,688,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Avanza Fonder AB grew its position in Disc Medicine by 54.0% during the third quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock worth $110,000 after buying an additional 585 shares during the period. Ameritas Investment Partners Inc. boosted its stake in shares of Disc Medicine by 8.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock worth $133,000 after acquiring an additional 206 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Disc Medicine by 383.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,975 shares of the company’s stock worth $211,000 after acquiring an additional 3,152 shares during the period. DNB Asset Management AS purchased a new position in Disc Medicine in the 2nd quarter valued at approximately $243,000. Finally, Bryce Point Capital LLC purchased a new position in Disc Medicine in the 3rd quarter valued at approximately $259,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Insider Buying and Selling

In other news, CFO Jean M. Franchi sold 7,081 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $65.47, for a total transaction of $463,593.07. Following the completion of the transaction, the chief financial officer owned 71,343 shares of the company’s stock, valued at $4,670,826.21. This represents a 9.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Jonathan Yen-Wen Yu sold 3,231 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total transaction of $203,100.66. Following the completion of the sale, the chief operating officer owned 54,324 shares of the company’s stock, valued at approximately $3,414,806.64. The trade was a 5.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 292,492 shares of company stock worth $25,423,925 over the last ninety days. Insiders own 3.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on IRON shares. Raymond James Financial reiterated a “market perform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. BMO Capital Markets decreased their price objective on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 17th. TD Cowen restated a “buy” rating on shares of Disc Medicine in a report on Friday, December 19th. Wells Fargo & Company lifted their target price on shares of Disc Medicine from $78.00 to $79.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, Morgan Stanley set a $75.00 price target on shares of Disc Medicine in a research report on Tuesday, February 17th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $104.80.

Disc Medicine Trading Down 1.2%

Shares of IRON opened at $60.34 on Friday. Disc Medicine, Inc. has a fifty-two week low of $30.82 and a fifty-two week high of $99.50. The company has a market capitalization of $2.28 billion, a PE ratio of -10.07 and a beta of 0.87. The stock has a fifty day moving average of $73.08 and a two-hundred day moving average of $75.48. The company has a debt-to-equity ratio of 0.04, a quick ratio of 23.45 and a current ratio of 21.94.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.62) EPS for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.07. The business had revenue of ($19.88) million during the quarter, compared to analysts’ expectations of $0.15 million. As a group, analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.